Skip to main content
Erschienen in: World Journal of Urology 4/2010

01.08.2010 | Original Article

Photodynamic diagnosis in patients with T1G3 bladder cancer: influence on recurrence rate

verfasst von: Peter Stanislaus, Dirk Zaak, Thomas Stadler, Stefan Tritschler, Ruth Knüchel, Christian G. Stief, Alexander Karl

Erschienen in: World Journal of Urology | Ausgabe 4/2010

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Therapeutic strategies on treatment of T1G3 urothelial cancer of the urinary bladder are controversial. The objective of this study was to investigate the impact of photodynamic diagnosis (PDD) on the recurrence-free survival rate of patients with the initial diagnosis of T1G3 bladder cancer.

Patients and methods

Between 1995 and 2007, 153 patients were treated for T1G3 bladder cancer at our institution. In 77 patients, initial TUR-BT was performed under PDD condition at our hospital, and 76 patients underwent TUR-BT in a standard white light setting at other institutions. PDD was performed either using 5-aminolevulinate or hexaminolevulinate for induction of fluorescence. Average follow-up was 53.9 months. Fisher’s exact test and Kaplan–Meier method were used to test data for significance.

Results

Of the 77 patients who were treated using PDD at initial TUR-BT, recurrence was observed in 23 (29.9%) cases, whereas 43 of 76 (56.6%) patients treated without PDD showed recurrence (P < 0.001). The detection rate of additional carcinoma in situ was 35.4% in the PDD group versus 21.8% in the white light group (P = 0.077). A limitation of the present study is the retrospective, monocentre setting, which is more likely to be biased.

Conclusion

PDD during initial TUR-BT in T1G3 bladder cancer seems to reduce significantly the rate of recurrence in our study population. Therefore, PDD seems to be associated with superior initial tumour control and more effective tumour treatment even in patients with highly aggressive tumours like T1G3 bladder cancer.
Literatur
1.
Zurück zum Zitat Soloway MS, Sofer M, Vaidya A (2002) Contemporary management of stage T1 transitional cell carcinoma of the bladder. J Urol 167:1573–1583CrossRefPubMed Soloway MS, Sofer M, Vaidya A (2002) Contemporary management of stage T1 transitional cell carcinoma of the bladder. J Urol 167:1573–1583CrossRefPubMed
2.
Zurück zum Zitat Denzinger S, Burger M, Walter B, Knuechel R, Roessler W, Wieland WF, Filbeck T (2007) Clinically relevant reduction in risk of recurrence of superficial bladder cancer using 5-aminolevulinic acid-induced fluorescence diagnosis: 8 year results of prospective randomized study. Urology 69:675–679CrossRefPubMed Denzinger S, Burger M, Walter B, Knuechel R, Roessler W, Wieland WF, Filbeck T (2007) Clinically relevant reduction in risk of recurrence of superficial bladder cancer using 5-aminolevulinic acid-induced fluorescence diagnosis: 8 year results of prospective randomized study. Urology 69:675–679CrossRefPubMed
3.
Zurück zum Zitat Herr HW (1997) Tumour progression, survival in patients with T1G3 bladder tumours, 15 year outcome. Br J Urol 80:762–765PubMed Herr HW (1997) Tumour progression, survival in patients with T1G3 bladder tumours, 15 year outcome. Br J Urol 80:762–765PubMed
4.
Zurück zum Zitat Bono AV, Lovisolo JA, Saredi G (2003) Transurethral resection and sequential chemo-immunoprophylaxis in primary T1G3 bladder cancer. Eur Urol 37:478–483CrossRef Bono AV, Lovisolo JA, Saredi G (2003) Transurethral resection and sequential chemo-immunoprophylaxis in primary T1G3 bladder cancer. Eur Urol 37:478–483CrossRef
5.
Zurück zum Zitat Catanzaro F, Torelli F, Catanzaro M, Cappellano F, Pizzoccaro M, Baruffi M, Sironi D, Pozzoli GL (1996) Conservative treatment of high-risk (T1G3) transitional carcinoma. Arch Ital Urol Androl 68:21–24PubMed Catanzaro F, Torelli F, Catanzaro M, Cappellano F, Pizzoccaro M, Baruffi M, Sironi D, Pozzoli GL (1996) Conservative treatment of high-risk (T1G3) transitional carcinoma. Arch Ital Urol Androl 68:21–24PubMed
6.
Zurück zum Zitat Cheng L, Weaver AL, Neumann RM, Scherer BG, Bostwick DG (1999) Sub staging of T1 bladder carcinoma based on the depth of invasion as measured by micrometer: a new proposal. Cancer 86:1035–1043CrossRefPubMed Cheng L, Weaver AL, Neumann RM, Scherer BG, Bostwick DG (1999) Sub staging of T1 bladder carcinoma based on the depth of invasion as measured by micrometer: a new proposal. Cancer 86:1035–1043CrossRefPubMed
7.
Zurück zum Zitat Patard J, Moudouni S, Saint F, Rioux-Leclercq N, Manunta A, Guy L, Ballanger P, Lanson Y, Hajri M, Irani J, Guille F, Beurton D, Lobel B (2001) Tumour progression and survival in patients with T1G3 bladder tumours: multicentric retrospective study comparing 94 patients treated during 17 years. Urology 58:551–556CrossRefPubMed Patard J, Moudouni S, Saint F, Rioux-Leclercq N, Manunta A, Guy L, Ballanger P, Lanson Y, Hajri M, Irani J, Guille F, Beurton D, Lobel B (2001) Tumour progression and survival in patients with T1G3 bladder tumours: multicentric retrospective study comparing 94 patients treated during 17 years. Urology 58:551–556CrossRefPubMed
8.
Zurück zum Zitat van der Meijden AP, Sylvester R, Oosterlinck W, Solsona E, Boehle A, Lobel B, Rintala E (2005) EAU guidelines on the diagnosis and treatment of urothelial carcinoma in situ. Eur Urol 48:363–371PubMed van der Meijden AP, Sylvester R, Oosterlinck W, Solsona E, Boehle A, Lobel B, Rintala E (2005) EAU guidelines on the diagnosis and treatment of urothelial carcinoma in situ. Eur Urol 48:363–371PubMed
9.
Zurück zum Zitat Hungerhuber E, Stepp H, Kriegmair M, Stief C, Hofstetter A, Hartmann A, Knuechel R, Karl A, Tritschler S, Zaak D (2007) Seven years’ experience with 5-aminolevulinic acid in detection of transitional cell carcinoma of the bladder. Urology 69:260–264CrossRefPubMed Hungerhuber E, Stepp H, Kriegmair M, Stief C, Hofstetter A, Hartmann A, Knuechel R, Karl A, Tritschler S, Zaak D (2007) Seven years’ experience with 5-aminolevulinic acid in detection of transitional cell carcinoma of the bladder. Urology 69:260–264CrossRefPubMed
10.
Zurück zum Zitat Kriegmair M, Zaak D, Stepp H, Stepp H, Baumgartner R, Knuechel R, Hofstetter A (1999) Transurethral resection and surveillance of bladder cancer supported by 5-aminolevulinic acid-induced fluorescence endoscopy. Eur Urol 36:386–392CrossRefPubMed Kriegmair M, Zaak D, Stepp H, Stepp H, Baumgartner R, Knuechel R, Hofstetter A (1999) Transurethral resection and surveillance of bladder cancer supported by 5-aminolevulinic acid-induced fluorescence endoscopy. Eur Urol 36:386–392CrossRefPubMed
11.
Zurück zum Zitat Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, Sarosdy MF, Bohl RD, Grossman HB, Beck TM, Leimert JT, Crawford ED (2000) Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized southwest oncology group study. J Urol 163:1124–1129CrossRefPubMed Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, Sarosdy MF, Bohl RD, Grossman HB, Beck TM, Leimert JT, Crawford ED (2000) Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized southwest oncology group study. J Urol 163:1124–1129CrossRefPubMed
12.
Zurück zum Zitat Bohle A, Bock PR (2004) Intravesical bacille Calmette-Guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumour progression. Urology 63:682–686CrossRefPubMed Bohle A, Bock PR (2004) Intravesical bacille Calmette-Guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumour progression. Urology 63:682–686CrossRefPubMed
13.
Zurück zum Zitat Herr HW, Dalbagni G (2003) Defining bacillus Calmette-Guerin refractory superficial bladder tumours. J Urol 169:1706–1708CrossRefPubMed Herr HW, Dalbagni G (2003) Defining bacillus Calmette-Guerin refractory superficial bladder tumours. J Urol 169:1706–1708CrossRefPubMed
14.
Zurück zum Zitat Dalbagni G, Russo P, Sheinfeld J, Mazumdar M, Tong W, Rabbani F, Donat MS, Herr HW, Sogani P, de Palma D, Bajorin D (2002) Phase I trial of intravesical gemcitabine in bacillus Calmette-Guerin-refractory transitional-cell carcinoma of the bladder. J Clin 20:3193–3198 Dalbagni G, Russo P, Sheinfeld J, Mazumdar M, Tong W, Rabbani F, Donat MS, Herr HW, Sogani P, de Palma D, Bajorin D (2002) Phase I trial of intravesical gemcitabine in bacillus Calmette-Guerin-refractory transitional-cell carcinoma of the bladder. J Clin 20:3193–3198
15.
Zurück zum Zitat Solsona E, Iborra I, Dumont R, Rubio-Briones J, Casanova J, Almenar S (2000) The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer. J Urol 164:685–689CrossRefPubMed Solsona E, Iborra I, Dumont R, Rubio-Briones J, Casanova J, Almenar S (2000) The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer. J Urol 164:685–689CrossRefPubMed
16.
Zurück zum Zitat Filbeck T, Pichlmeier U, Knuechel R, Wieland WF, Roessler W (2002) Clinically relevant improvement of recurrence-free survival with 5-aminolevulinic acid induced fluorescence diagnosis in patients with superficial bladder tumour. J Urol 168:67–71CrossRefPubMed Filbeck T, Pichlmeier U, Knuechel R, Wieland WF, Roessler W (2002) Clinically relevant improvement of recurrence-free survival with 5-aminolevulinic acid induced fluorescence diagnosis in patients with superficial bladder tumour. J Urol 168:67–71CrossRefPubMed
17.
Zurück zum Zitat Schumacher MC, Holmang S, Davidsson T, Friedrich B, Pedersen J, Wiklund NP (2010) Transurethral resection of non-muscle-invasive bladder transitional cell cancers with or without 5-aminolevulinic Acid under visible and fluorescent light: results of a prospective, randomised, multicentre study. Eur Urol 57:293–299CrossRefPubMed Schumacher MC, Holmang S, Davidsson T, Friedrich B, Pedersen J, Wiklund NP (2010) Transurethral resection of non-muscle-invasive bladder transitional cell cancers with or without 5-aminolevulinic Acid under visible and fluorescent light: results of a prospective, randomised, multicentre study. Eur Urol 57:293–299CrossRefPubMed
18.
Zurück zum Zitat Jakse G, Algaba F, Malmstrom PU, Oosterlinck W (2004) A second-look TUR in T1 transitional cell carcinoma: why? Eur Urol 45:539–546CrossRefPubMed Jakse G, Algaba F, Malmstrom PU, Oosterlinck W (2004) A second-look TUR in T1 transitional cell carcinoma: why? Eur Urol 45:539–546CrossRefPubMed
19.
Zurück zum Zitat Kriegmair M, Zaak D, Rothenberger KH, Rassweiler J, Jocham D, Eisenberger F, Tauber R, Stenzl A, Hofstetter A (2002) Transurethral resection for bladder cancer using 5-aminolevulinic acid induced fluorescence endoscopy versus white light endoscopy. J Urol 168:475–478CrossRefPubMed Kriegmair M, Zaak D, Rothenberger KH, Rassweiler J, Jocham D, Eisenberger F, Tauber R, Stenzl A, Hofstetter A (2002) Transurethral resection for bladder cancer using 5-aminolevulinic acid induced fluorescence endoscopy versus white light endoscopy. J Urol 168:475–478CrossRefPubMed
20.
Zurück zum Zitat Sylvester RJ (2007) Intravesical chemotherapy in non-muscle-invasive bladder cancer: what schedule and duration of treatment? Eur Urol 52:951–953CrossRefPubMed Sylvester RJ (2007) Intravesical chemotherapy in non-muscle-invasive bladder cancer: what schedule and duration of treatment? Eur Urol 52:951–953CrossRefPubMed
21.
Zurück zum Zitat Jocham D, Witjes F, Wagner S, Zeylemaker B, Van MJ, Grimm MO, Muschter R, Popken G, Konig F, Knuchel R, Kurth KH (2005) Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study. J Urol 174:862–866CrossRefPubMed Jocham D, Witjes F, Wagner S, Zeylemaker B, Van MJ, Grimm MO, Muschter R, Popken G, Konig F, Knuchel R, Kurth KH (2005) Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study. J Urol 174:862–866CrossRefPubMed
Metadaten
Titel
Photodynamic diagnosis in patients with T1G3 bladder cancer: influence on recurrence rate
verfasst von
Peter Stanislaus
Dirk Zaak
Thomas Stadler
Stefan Tritschler
Ruth Knüchel
Christian G. Stief
Alexander Karl
Publikationsdatum
01.08.2010
Verlag
Springer-Verlag
Erschienen in
World Journal of Urology / Ausgabe 4/2010
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-010-0574-y

Weitere Artikel der Ausgabe 4/2010

World Journal of Urology 4/2010 Zur Ausgabe

Ambulantisierung: Erste Erfahrungen mit dem Hybrid-DRG

02.05.2024 DCK 2024 Kongressbericht

Die Hybrid-DRG-Verordnung soll dazu führen, dass mehr chirurgische Eingriffe ambulant durchgeführt werden, wie es in anderen Ländern schon länger üblich ist. Die gleiche Vergütung im ambulanten und stationären Sektor hatten Niedergelassene schon lange gefordert. Aber die Umsetzung bereitet ihnen doch Kopfzerbrechen.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Harninkontinenz: Netz-Op. erfordert über lange Zeit intensive Nachsorge

30.04.2024 Harninkontinenz Nachrichten

Frauen mit Belastungsinkontinenz oder Organprolaps sind nach einer Netz-Operation keineswegs beschwerdefrei. Vielmehr scheint die Krankheitslast weiterhin hoch zu sein, sogar höher als von harninkontinenten Frauen, die sich nicht haben operieren lassen.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.